Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Insuplant · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Insuman Implantable | EXPERIMENTAL | Starting dose regimen is the same as the one administered to the patient prior randomization, then the insulin odse is established by the investigator on a patient basis in respect to the American Diabetes Association guidelines. |
| Insuplant | ACTIVE_COMPARATOR | Starting dose regimen is the same as the one administered to the patient prior randomization, then the insulin odse is established by the investigator on a patient basis in respect to the American Diabetes Association guidelines. |
| Name | Type | Description |
|---|---|---|
| HUMAN INSULIN (BIOSYNTHETIC) | DRUG | Pharmaceutical form: solution for infusion Route of administration: Intraperitoneal use Dose regimen: 400 IU/ml |
| Insuplant | DRUG | Pharmaceutical form:solution for infusion Route of administration: Intraperitoneal use Dose regimen: |
Inclusion criteria: 1. Patients already treated with Insuplant 400 IU/ml via a Medtronic Implantable System 2007 2. Glycosylated hemoglobin ≤9.0% 3. Patient showing a percentage of error at refill equal or below 20% 4. Patient undergoing NaOH rinse procedure of at least 10 minutes period with or wi...
Insuplant is an investigational small molecule being developed by Sanofi for the treatment of Type 1 Diabetes Mellitus. It is designed for use with an implantable pump system to deliver insulin therapy. As of the available data, it is in Phase 3 clinical development and is not yet approved.
Insuplant is a small molecule intended for use in Type 1 Diabetes Mellitus. The available information does not specify a molecular target or target class for Insuplant. It is being evaluated in a Phase 3 clinical trial for its benefit and risk profile when used with an implantable pump system.
Insuplant is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi is conducting clinical trials to evaluate the safety and efficacy of Insuplant in patients with Type 1 Diabetes Mellitus.
Insuplant is currently in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 3 trial, NCT01194882, has been completed, evaluating the benefit and risk of Insuplant compared to an active control in patients with Type 1 Diabetes.
Insuplant has been studied in one Phase 3 clinical trial, NCT01194882, titled 'Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes'. This trial was completed and enrolled 479 participants across Belgium, France, Netherlands, and Sweden.
Insuplant is being compared to Insuman Implantable in a clinical trial, but they are not the same drug. The trial evaluates the benefit and risk of Insuman Implantable versus Insuplant, both used with the Medtronic MiniMed implantable pump system in patients with Type 1 Diabetes. Insuplant is a separate investigational product.